Relevance intrinsic sympathomimetic activity beta blockers Intrinsic sympathomimetic activity ISA group beta blockers able beta-adrenergic receptors agonist effect stimulating effects catecholamines antagonist effect competitive way Partial agonists submaximal response bound receptors maximal occupancy isolated rat atrium acebutolol maximal stimulatory effect maximal effect full beta agonist isoproterenol presence ISA results resting bradycardia reduction cardiac output beta blockers ISA long term partial beta agonists arterial vasodilation arterial compliance additional beneficial effects treatment hypertension beta blockers ISA adverse effects plasma lipoproteins long-term treatment addition presence ISA up-regulation beta adrenoceptors beta blockers ISA presence ISA conflicting issue use beta blockers secondary prevention myocardial infarction impressive results Acebutolol Prevention Secondary Infarction trial high-risk patients myocardial infarction show acebutolol beta blocker moderate partial agonist activity effective postinfarction mortality rate different hemodynamic profile beta blockers ISA partial beta agonists intriguing pharmacologic class drugs prospective clinical trials 